In an embodiment, is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein none of X 10 , X 12 , X 13 , X 14 , X 16 , X 17 , X 19 , X 20 , X 21 , X 23 , X 24 , X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , and X 40 is a substituent that contains a fatty acid
Glucagon receptor agonism Glucagon receptor activation increases energy expenditure, improves liver health, delays gastric emptying, and promotes fat breakdown
SGLT2 inhibitors are usually added into treatment for people with type 2 diabetes who also have cardiovascular disease or are at risk of cardiovascular disease
The results are presented in Table 2
Am J Med Genet (2001) 102(1):1820
Magensaftresistente Kapseln: Verbessern die Resorption, da die empfindlichen Wirkstoffe nicht schon durch die Magensure gespalten, sondern erst im Zwlffingerdarm freigesetzt werden